ARTICLE INFO

Article Type

Original Research

Authors

Roomande   N. (1)
Saremi   A. (2)
Pooladi   A. (3)
Zare   A. (*2)






(1) Department of Immunology, Sarem Fertility & Infertility Research Center, Sarem Women’s Hospital, Tehran, Iran
(2) Sarem Fertility & Infertility Research Center, Sarem Women’s Hospital, Tehran, Iran
(3) Department of Genetic, Sarem Fertility & Infertility Research Center, Sarem Women’s Hospital, Tehran, Iran

Correspondence

Address: Sarem Women's Hospital, End of Phase 3, Ekbatan Town, Tehran, Iran
Phone: +98 (21) 66470888
Fax: +98 (21) 44670885
ahadzr@gmail.com

Article History

Received:  October  30, 2017
Accepted:  April 5, 2018
ePublished:  June 15, 2019

BRIEF TEXT


Pregnancy transiently causes immunosuppression, which increases the risk of infection in pregnant women [1]. As infections such as congenital rubella are controlled by vaccination, an infection caused by Toxoplasma, Cytomegalovirus (CMV), rubella, and Varicella-zoster virus (VZV) that can cause intrauterine infections and fetal abnormalities have been considered [2].

... [3-9]. CMV and VZV are from herpes viruses and potentially teratogenic [10]. ... [11]. VZV is one of the several infections that it has serious complications for pregnant women and their fetus [12]. ... [13-16]. Rubella is a mild infectious disease that occurs after childhood vaccination [17].

The aim of this study was to determine the prevalence and immunity of toxoplasma, rubella, CMV, and VZV infections in pregnant women.

This is a descriptive study.

This study was performed on the basis of normal data of people, who were referred to Sarem Hospital in Tehran in the second half of 2016.

Data collection was based on 1237 patients' records.

The data including toxo (Toxo IgM and Toxo IgG), CMV (CMV IgG and CMV IgM), rubella (Rubella IgM and Rubella IgG), and VZV (VZV IgM and VZV IgG) tests were extracted. The experiments were carried by ELISA method, using commercial kits (Vircell; Spain). Data analysis was performed, using SPSS 22 software.

The mean age of the women was 32.00±4.97 years, each of whom had performed one or more of the tests in this study. 40.4% of the subjects were in the age group of 31-35 years old. Of all the tests, 975 cases were for Toxo IgM (78.4%), 977 cases for Toxo IgG (78.5%), 878 cases for Rubella IgM (70.6%), 875 cases for Rubella IgG (70.4%) 604 cases for CMV IgM (48.6%), 605 cases for CMV IgG (48.7%), 394 cases for VZV IgM (31.7%), and 393 cases for VZV IgG (31.6%). Toxo IgM test was negative in 972 (99.7%) patients and positive only in 0.3% of them. The mean age of the positive and negative results was 31.91±5.00 and 33±2 years, which was not statistically significant (p>0.05). Rubella IgM test was negative in all subjects, who performed the test and the mean age of the group was 32.52±5.50. Toxo IgG test was positive in 97% of the subjects and negative in 3% of them. The mean age of the positive and negative cases related to this test was 31.84±4.90 and 34.5±17.5 years, which was not statistically significant (p=0.14). Rubella IgG test was positive in 757 cases (86.5%) and negative in 118 cases (13.5%). The mean age of the positive and negative results was 32.29±5.30 and 31.75±4.84 years, which was not statistically significant (p=0.307). CMV IgM test was negative in 99.8% and positive only in 0.2%. The mean age of subjects with a negative test was 31.64±4.80 and 41.0±1.2 years in subjects with a positive test. The CMV IgG test was positive in 86.8% of the patients. The mean age of the positive and negative cases of CMV IgG was 31.40± 29.71 and 34.67±6.83, respectively. VZV IgM test was negative in all cases (100%), but the VZV IgG test was positive in 98.5% and negative in 1.5%. The mean age of the positive and negative cases was 31.40±29.71 and 34.67±6.83 years, respectively. There was no significant difference in the age distribution of women in the CMV and VZV IgG positive and negative groups (p>0.05). Regarding the fact that most tests were in women with the age range of 31-35 years, the most positive and negative cases were in the same group.

... [18-24]. In the present study, the prevalence of Toxo IgM and Toxo IgG antibodies was 0.3% and 97%, respectively. Toxoplasma is involved in abortion. In a study in 124 women with abortion history, the prevalence of IgG and IgM antibodies was 79.03% and 15.32%, respectively [25]. In the present study, 2% of all patients were positive in terms of CMV IgM, indicating an active infection that had recently occurred. In this study, the incidence of CMV infection was reduced in comparison with the study conducted at the Avicenna Infertility Treatment Center, which was performed on 332 CMV IgM tests. In another study, CMV IgM test was reported 5.4% and positive in women of reproductive age [26]. ... [27]. In this study, the safety level to VZV was more than 98.5%. A survey of 290 women in Germany showed 97% of their safety [28]. Also, the IgG anti-VZV antibody level in the assessment of 2807 women in Argentina showed immunity level 98.5% relative to VZV [29]. In this study, immune response to rubella virus in women of reproductive age was 86.5%. In a study, 271 women referring to Birjand Health Center were evaluated; immune response to rubella was reported 95.2% [30].

It is suggested that in future studies, patients, who have performed all the tests, should be evaluated.

Limitations of this study may include the lack of adequate information on demographic characteristics of the patients.

99.7% of women in terms of Toxo IgM, 99.8% in terms of CMV IgM and all of them in terms of Rubella IgM and VZV IgM were negative. Also, 97% of the subjects in terms of Toxo IgG, 86.5% in terms of Rubella IgG, 86.8 in terms of CMV IgG, and 98.5% in terms of VZV IgG were positive.

None declared by the authors.

None declared by the authors.

None declared by the authors.

None declared by the authors.


CITIATION LINKS

[1] Mellor AL, Munn DH. Extinguishing maternal immune responses during pregnancy: implications for immunosuppression. Semin Immunol. 2001;13(4):213-8.
[2]Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpaa R. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. British J Obstet Gynaecol. 2005;112(1):50-6.
[3]Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013;114:125-45.
[4]Cenci-Goga BT, Rossitto PV, Sechi P, McCrindle CM, Cullor JS. Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog Dis. 2011;8(7):751-62.
[5]Goldstein EJ, Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554-66.
[6]Robert-Gangneux F, Murat JB, Fricker-Hidalgo H, Brenier-Pinchart MP, Gangneux JP, Pelloux H. The placenta: a main role in congenital toxoplasmosis? Trends Parasitol. 2011;27(12):530-6.
[7]Dabritz HA, Conrad PA. Cats and Toxoplasma: implications for public health. Zoonoses Public Health. 2010;57(1):34-52.
[8]Wang T, Liu M, Gao XJ, Zhao ZJ, Chen XG, Lun ZR. Toxoplasma gondii: the effects of infection at different stages of pregnancy on the offspring of mice. Exp Parasitol. 2011;127(1):107-12.
[9]Bessieres MH, Berrebi A, Cassaing S, Fillaux J, Cambus JP, Berry A, et al. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem Inst Oswaldo Cruz. 2009;104(2):389-92.
[10]Scott LL, Hollier LM, Dias K. Perinatal herpesvirus infections: herpes simplex, varicella and cytomegalovirus. Infect Dis Clin North Am. 1997;11(1):27-53.
[11]Yinon Y, Farine D, Yudin MH. Screening, diagnosis and management of cytomegalovirus infection in pregnancy. Obstet Gynecolo Surv. 2010;65(11):736-43.
[12]Daley AJ, Thorpe S, Garland SM. Varicella and the pregnant woman: prevention and management. Aust N Z J Obstet Gynaecol. 2008;48(1):26-33.
[13]Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365-76.
[14] Field N, Amirthalingam G, Waight P, Andrews N, Ladhani SN, van Hoek AJ, et al. Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England. Vaccine. 2014;32(10):1213-7.
[15]Kodur VV, Hegde DG. Congenital varicella syndrome. Indian pediatr. 2016;53(3):269.
[16]Maple PC, Gray J, Brown K, Brown D. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection. J Virol methods. 2009;157(1):90-2.
[17] Hamdan HZ, Abdelbagi IE, Nasser NM, Adam I. Seroprevalence of cytomegalovirus and rubella among pregnant women in western Sudan. Virol J. 2011;8(1):217.
[18] Uyar Y, Balci A, Akcali A, Cabar C. Prevalence of rubella and cytomegalovirus antibodies among pregnant women in northern Turkey. New Microbiol. 2008;31(4):451-5.
[19]Calimeri S, Capua A, La Fauci V, Squeri R, Grillo OC, Giudice DL. Prevalence of serum anti-rubella virus antibodies among pregnant women in southern Italy. Int J Gynaecol Obstet. 2012;116(3):211-3.
[20]Best JM, O'Shea S, Tipples G, Davies N, Al-Khusaiby SM, Krause A, et al. Interpretation of rubella serology in pregnancy--pitfalls and problems. British Med J. 2002;325(7356):147-8.
[21]Jumaian NF. Seroprevalence and risk factors for Toxoplasma infection in pregnant women in Jordan. East Mediterr Health J. 2005;11(1-2):45-51.
[22] Rajaii M, Pourhassan A, Asle-Rahnamaie-Akbari N, Aghebati L, Xie JL, Goldust M, et al. Seroepidemiology of toxoplasmosis in childbearing women of Northwest Iran. Infez Med. 2013;21(3):194-200.
[23] Mohaghegh MA, Yazdani H, Hadipour M, Namdar F, Azami M, Kalani H, et al. Seroprevalence of Toxoplasma gondii Infection among Patients Admitted to Al-Zahra Hospital, Isfahan, Iran. J Ayub Med Coll Abbottabad. 2015;27(4):767-70.
[24] Mohammadi A, Shojaee S, Salimi M, Zareei M, Mohebali M, Keshavarz H. Seroepidemiological Study of Toxoplasmosis in Women Referred to Arak Marriage Consulting Center during 2012-2013. Iran J Public Health. 2015;44(5):654-8.
[25] Saki J, Mohammadpour N, Moramezi F, Khademvatan S. Seroprevalence of Toxoplasma gondii in women who have aborted in comparison with the women with normal delivery in Ahvaz, southwest of Iran. Sci World J. 2015;2015:764369.
[26] Chakravarty A, Kashyap B, Rathi K. The seroepidemiological study on cytomegalovirus in women of child-bearing age with special reference to pregnancy and maternal-fetal transmission. Indian J Pathol Microbiol. 2005;48(4):518-21.
[27] Tabatabaee M, Tayyebi D. Seroepidemiologic study of human cytomegalovirus in pregnant women in Valiasr Hospital of Kazeroon, Fars, Iran. J Matern-Fetal Neonatal Med. 2009;22(6):517-21.
[28]Sauerbrei A, Prager J, Bischoff A, Wutzler P. Antibodies against vaccine-preventable diseases in pregnant women and their offspring; Measles, mumps, rubella, poliomyelitis, and varicella. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2004;47(1):10-5.
[29]Dayan GH, Panero MS, Debbag R, Urquiza A, Molina M, Prieto S, et al. Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002. J clin microbiol. 2004;42(12):5698-704.
[30]Azarkar Z, Afshar M, Hoseini SM. Evaluation of anti-rubella antibody in women of reproductive age referring to Birjand health center in 2001-2002. J Shahid Sadoughi Univ Med Sci. 2004;12(4):61-4.